Filing Flows

Filing Flows › Companies › ENvue Medical › Cash flow

ENvue Medical cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$2.7M in Q2 2026 · −$11.7M over twelve months

Operating cash flow−$2.7M
Capital spending−$27K
Free cash flow−$2.7M
Cash conversion cycle400 days

Analysis

In Q2 2026, ENvue Medical generated −$2.7M of operating cash flow and spent $27K on capital projects, leaving free cash flow of −$2.7M. That is $669K more than in Q2 2025 (−$3.4M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$11.6M; the largest uses were operating cash flow ($11.6M), capital spending ($95K); besides operations, cash came from other financing ($8.8M); the cash balance fell by $2.9M.

Operating cash flow was −$2.7M against net income of −$4.9M. The largest differences: inventory −$315K, depreciation & amortization +$219K, payables +$133K.

Its cash conversion cycle was 400 days (receivables 102 + inventory 437 − payables 139).

Free cash flow

ENvue Medical: free cash flow by quarterENvue Medical: free cash flow by quarter−$836KQ3 2024−$548KQ4 2024−$1.3MQ1 2025−$3.4MQ2 2025−$2.0MQ3 2025−$2.7MQ4 2025−$4.3MQ1 2026−$2.7MQ2 2026
Operating cash flow less capital spending.
ENvue Medical: operating cash flow against capital spendingENvue Medical: operating cash flow against capital spendingOperating cash flowCapital spending−$836K$0Q3 2024−$548K$0Q4 2024−$1.3M$5KQ1 2025−$3.4M$4KQ2 2025−$2.0M$28KQ3 2025−$2.7M$23KQ4 2025−$4.3M$17KQ1 2026−$2.7M$27KQ2 2026
Latest (Q2 2026): Operating cash flow −$2.7M, Capital spending $27K.

Capital allocation, year by year

ENvue Medical: where the cash came from (up) and went (down), by fiscal yearENvue Medical: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow −$4.4MFY2021: Shares issued $5.0MFY2021: Capital spending −$3K$5.0MFY2021FY2022: Operating cash flow −$7.0MFY2022: Shares issued $2.1MFY2022: Capital spending −$3K$2.1MFY2022FY2023: Operating cash flow −$3.6MFY2023: Shares issued $4.2MFY2023: Capital spending −$1K$4.2MFY2023FY2024: Operating cash flow −$2.5MFY2024: Shares issued $1KFY2024: Capital spending −$3K$1KFY2024FY2025: Operating cash flow −$9.4MFY2025: Net borrowing −$1.1MFY2025: Shares issued $19.2MFY2025: Capital spending −$60K$19.2MFY2025
Over these 5 years operating cash flow totalled −$26.9M; the largest uses were operating cash flow ($26.9M) and net borrowing ($1.1M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$1.1M
Debtnone
Net cash$1.1M
Cash runway1 month

ENvue Medical is burning cash: its operations consume cash, a free cash flow of −$11.7M a year at the current rate against $1.1M of cash and investments: a runway of about 1 month before any new financing.

Where the cash came from and went

ENvue Medical: sources (+) and uses (−) of cash, Q2 2026ENvue Medical: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$2.7MOther financing$1.6MCash drawn (+) / kept (−)$1.1MCapital spending−$27K
ENvue Medical: sources (+) and uses (−) of cash, TTM to Q2 2026ENvue Medical: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$11.6MOther financing$8.8MCash drawn (+) / kept (−)$2.9MCapital spending−$95KNot reconciled$5K

From profit to cash

ENvue Medical: net income to operating cash flow, Q2 2026ENvue Medical: net income to operating cash flow, Q2 2026Net income−$4.9MDepreciation & amortization$219KReceivables$126KInventory−$315KPayables$133KOperating cash flow−$2.7M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 2026102437139400
Q1 20264329391245
Q4 20258030982307
Q3 20252338466342
Q2 20254436336371
Q1 20252028913295
Q4 2024701269211319
Q3 202413188622995

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$2.7M−$27K——$1.1M−$2.7M
Q1 2026−$4.3M−$17K——$2.0M−$4.3M
Q4 2025−$2.7M−$23K—$2.0M$2.7M−$2.7M
Q3 2025−$2.0M−$28K—$8.9M−$2.9M−$2.0M
Q2 2025−$3.4M−$4K−$690K—−$3.5M−$3.4M
Q1 2025−$1.3M−$5K$1.1M—$151K−$1.3M
Q4 2024−$548K———$553K−$548K
Q3 2024−$836K——−$27K$865K−$836K

ENvue Medical: income statement and cash flow

ENvue Medical, Q2 2026: revenue $239K (-52% year over year). The chart follows the revenue to costs, profit and cash.

ENvue Medical: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.